Skip to content

The Application and Advantages of Remifentanil Combined with Thoracic Paravertebral Nerve Block in Elderly Patients' Surgery

The Application and Advantages of Remifentanil Combined with Thoracic Paravertebral Nerve Block in Elderly Patients' Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500096598
Enrollment
Unknown
Registered
2025-01-26
Start date
2025-01-28
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative cognitive dysfunction and other postoperative anesthesia related complications

Interventions

Remifentanil Group:The use of remifentanil during the process of anesthesia
Conventional Opioid Group:The use of sufentanil during the process of anesthesia
Remifentanil combined with thoracic paravertebral nerve block group.:The application of remifentanil combined with thoracic paravertebral nerve block during the process of anesthesia.
The application of conventional opioids combined with thoracic paravertebral nerve block.:The application of conventional opioids combined with thoracic paravertebral nerve block during the process of

Sponsors

The Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age>=65 years old; 2. Gender is not limited; 3. Elective surgery (such as general surgery, thoracic surgery, orthopedic spine surgery, urological surgery, gynecological surgery) is planned; 4. ASA Class I-III; 5. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with severe impairment of consciousness or psychiatric diseases (schizophrenia, mania, bipolar abnormalities, mental confusion, etc.) and cognitive dysfunction before surgery; 2. Severe cardiovascular and cerebrovascular events (acute heart failure, severe angina pectoris, or unstable angina or myocardial infarction, severe arrhythmia, pulmonary embolism, pulmonary edema, non-fatal stroke) within 3 months; 3. Local anesthesia surgery; 4. Patients who have undergone day surgery or are admitted and discharged within 48 hours.

Design outcomes

Primary

MeasureTime frame
Cognitive function test;Montreal Cognitive Assessment (MoCA);

Secondary

MeasureTime frame
Postoperative awakening time;The time of postoperative tracheal tube removal.;Pain score ;Blood routine test;Inflammatory factors;Immune factors;

Countries

China

Contacts

Public ContactPeng Wang

The Affiliated Hospital of Qingdao University

qduwpeng@126.com+86 186 6180 6571

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026